Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Director departure Inv. presentation Quarterly results
|
Carlyle Group Inc. (CG)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/03/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 10% stake in Soleno Therapeutics, Inc. |
08/18/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
08/18/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 12.3% stake in Soleno Therapeutics, Inc. |
08/02/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 4.2% stake in Vera Therapeutics, Inc. |
07/17/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8.1% stake in Carlyle Credit Income Fund |
07/05/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 5.5% stake in Vera Therapeutics, Inc. |
05/10/2023 |
SC 13D/A
| Carlyle Group Inc. has filed a Schedule 13D for Soleno Therapeutics, Inc. |
05/09/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8.2% stake in Reneo Pharmaceuticals, Inc. |
04/13/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 6.7% stake in Vera Therapeutics, Inc. |
04/13/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 3.4% stake in Exicure, Inc. |
02/23/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 9.2% stake in Spruce Biosciences, Inc. |
01/31/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8% stake in Jasper Therapeutics, Inc. |
12/20/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
08/11/2022 |
SC 13D/A
| Carlyle Group Inc. reports a 5.7% stake in Exicure, Inc. |
08/11/2022 |
SC 13D/A
| Carlyle Group Inc. reports a 11.1% stake in Vera Therapeutics, Inc. |
08/11/2022 |
SC 13D/A
| Carlyle Group Inc. reports a 5.4% stake in Adicet Bio, Inc. |
08/11/2022 |
SC 13D/A
| Carlyle Group Inc. reports a 6.4% stake in NuCana plc |
08/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
08/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
08/11/2022 |
SC 13D/A
| Carlyle Group Inc. reports a 8.5% stake in Reneo Pharmaceuticals, Inc. |
08/11/2022 |
SC 13D/A
| Carlyle Group Inc. reports a 7.7% stake in Spruce Biosciences, Inc. |
08/11/2022 |
SC 13D/A
| Carlyle Group Inc. reports a 15.4% stake in Jasper Therapeutics, Inc. |
07/27/2022 |
SC 13D/A
| Carlyle Group Inc. reports a 16% stake in CommScope Holding Company, Inc. |
06/14/2022 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 42.1% stake in The Carlyle Group Inc. |
11/19/2021 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 43.7% stake in The Carlyle Group Inc. |
08/31/2021 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 45.4% stake in The Carlyle Group Inc. |
08/17/2021 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 46.8% stake in The Carlyle Group Inc. |
08/06/2021 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 48% stake in The Carlyle Group Inc. |
07/28/2021 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 50.4% stake in The Carlyle Group Inc. |
07/13/2021 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 54.6% stake in The Carlyle Group Inc. |
03/19/2021 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 56.1% stake in The Carlyle Group Inc. |
01/08/2021 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 57.8% stake in The Carlyle Group Inc. |
11/17/2020 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 58.9% stake in The Carlyle Group Inc. |
07/06/2020 |
SC 13D/A
| Carlyle Group Management L.L.C. reports a 60.4% stake in The Carlyle Group Inc. |
|
|
|